Growth Metrics

Pfizer (PFE) Current Deferred Tax Assets (2016 - 2025)

Pfizer (PFE) has disclosed Current Deferred Tax Assets for 16 consecutive years, with $4.0 billion as the latest value for Q4 2025.

  • Quarterly Current Deferred Tax Assets rose 19.7% to $4.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 billion through Dec 2025, up 19.7% year-over-year, with the annual reading at $4.0 billion for FY2025, 19.7% up from the prior year.
  • Current Deferred Tax Assets for Q4 2025 was $4.0 billion at Pfizer, up from $3.9 billion in the prior quarter.
  • The five-year high for Current Deferred Tax Assets was $4.3 billion in Q4 2021, with the low at $2.5 billion in Q4 2022.
  • Average Current Deferred Tax Assets over 5 years is $3.5 billion, with a median of $3.6 billion recorded in 2022.
  • The sharpest move saw Current Deferred Tax Assets crashed 34.38% in 2022, then skyrocketed 53.97% in 2023.
  • Over 5 years, Current Deferred Tax Assets stood at $4.3 billion in 2021, then fell by 16.15% to $3.6 billion in 2022, then rose by 11.21% to $4.0 billion in 2023, then dropped by 16.69% to $3.3 billion in 2024, then grew by 19.7% to $4.0 billion in 2025.
  • According to Business Quant data, Current Deferred Tax Assets over the past three periods came in at $4.0 billion, $3.9 billion, and $4.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.